Latest Reimbursement News

Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.

6K Additive has completed a six-year, US$27.4 million secured loan with the US Export-Import Bank to expand production of critical metal powders in Pennsylvania. The financing gives the company access to project funding through June 2028, but the final interest rate and the expansion’s eventual output remain to be established.

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Hejaz High Income Active ETF delivered a 3.74% net return for the year, well below its reported 13.93% benchmark return. Net assets rose sharply to $9.64 million, but the increase was driven mainly by new applications rather than investment performance.

Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.

Aureka’s inferred gold resources climbed to 454.8koz in FY2026 as the company moved closer to production through a proposed acquisition of the Fiddlers Creek mine and Wedderburn mill. The shift comes with a $5.75 million annual loss, $5.97 million operating cash outflow and further equity funding.

GWR Group has swung to a $26.84 million FY2026 loss after impairing Gold Valley receivables and booking a $10.19 million rehabilitation provision linked to Wiluna West. The company still holds $37.13 million in cash, but its accounts warn of material uncertainty after a $19.85 million capital distribution to shareholders.

ACDC Metals enters FY27 with a larger Nevada exploration footprint and a 10-year licence over its Goschen Central rare earths project, but a sharply higher annual loss and ongoing funding needs remain part of the picture. The company plans up to 2,500 metres of reverse-circulation drilling at Mount Jackson in Q4 CY2026.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

IperionX has moved its Virginia titanium operation into 24/7 production, lifting nameplate powder capacity to about 200 tonnes a year while commissioning equipment aimed at higher-value components. The progress came alongside a US$66.8 million annual loss, US$63.5 million of operating and investing cash outflows, and continued reliance on government support, customer qualification and future capital.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.